Biote announces closing of secondary offering of 8,500,000 shares of common stock including full exercise of the underwriters' over-allotment option

Irving, texas--( business wire )--biote corp. (nasdaq: btmd) (“biote” or the “company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the closing of its previously announced underwritten public offering of 8,500,000 shares of its class a common stock by certain of its stockholders, including the full exercise of the underwriters' option to purchase 1,108,695 shares of class a common stock, at a price to the public of $3.00 per share. biote is not receiving any proceeds from the offering.
BTMD Ratings Summary
BTMD Quant Ranking